Global Human Tetanus Immunoglobulin Market Is Expected To Grow At a CAGR of 5.1% from 2020 to 2027


Tetanus is caused by the exposure to the microbe Clostridium tetani which is clinically manifested by autonomous nervous system dysfunction and muscle spasms. Human tetanus immunoglobulin mainly comprises of immunoglobulin in which the concentration of specific IgG to tetanus toxin is close to 100 IU/ml in nominal 250 IU vials. It serves as immediate prophylaxis in patients who have acquired tetanus prone injuries and whose previous immunization is not clear. Furthermore, it is also widely employed in patients showing deficiency in antibody production or vaccinated patients having high-risk wounds.

Children are leading the demography segment for the human tetanus immunoglobulin market. Immunization guidelines determined by pediatric surgeons across the globe emphasizing on the compulsory immunization of tetanus among children primarily drive the market growth. Adult demography will be showcasing comfortable market growth during the forecast period owing to the growing incidence of tetanus infection among individuals working in cattle and dairy industries and compulsory immunization of researchers engaged in performing preclinical trials of new drug entity.

Browse the full report Human Tetanus Immunoglobulin Market  - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at

Hospital pharmacy is currently dominating the distribution channel segment for the human tetanus immunoglobulin market. Side effects such as itching, reddening of the skin, swelling of eyes, hives, etc., makes it necessary for accurate drug dispensing of human tetanus immunoglobulin in the presence of hospital pharmacist. Retail pharmacy is expected to cater to exemplary market performance in the near future on account of its ability to provide medical aid to people residing in remote locations.

The Asia Pacific is representing the largest market share in the geography segment for the human tetanus immunoglobulin market. The rising prevalence of tetanus prone injuries primarily drives market growth in the region. As per the latest research citings presented by the World Health Organization (WHO), it is estimated that C.tetani is recovered from 30% of the patients suffering injuries in the South Asia region. Increasing public health awareness regarding the benefits of prophylaxis immunization in reducing the mortality rate associated with tetanus infection further propels the market growth. Europe is considered as the second-largest regional segment for human tetanus immunoglobulin on account of the domicile of key players such as Octapharma AG., Grifols SA., Kedrion S.p.A., CSL Behring, etc. Latin America is anticipated to be the fastest-growing regional segment for human tetanus immunoglobulin market due to the lucrative market opportunities presented to western giants to establish retail outlets & subsidiaries and developing healthcare infrastructure.

Pharmaceutical manufacturers actively engaged in the production of human tetanus immunoglobulin are Octapharma AG., Grifols SA., CSL Limited., Biotest AG., Kedrion S.p.A., Hualan Biological Engineering, Inc., Shire, Plc., CSL Behring., Bharat Serums, and Bio Products Laboratory Ltd.

Key Market Movements:

Rising prevalence of tetanus prone injuries worldwide

Increasing public health awareness regarding the benefits of prophylactic treatment in preventing and reducing the morbidity associated with tetanus infection

The proactive initiative adopted by government healthcare agencies pertaining to the free and compulsory immunization of children across the globe

Why Choose Us?

  • Comprehensive, Accurate, Reliable
  • Experienced Researcher Team
  • 24x7 Support

Website Secure By

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.